Australian Orphan Fee Waivers To Expire As Transition Period Ends
Executive Summary
The transition period for Australia’s new orphan drug program is coming to an end, and sponsors may need to take action if they want to keep their orphan status - and fee waivers - beyond the end of June.
You may also be interested in...
Australia Announces A “Fairer” Orphan Drugs Program, With New Eligibility And Validity Criteria
New orphan drug designations under Australia’s reformed program will lapse after six months, although there is a 12-month transitional period for existing designations.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.